Merus N.V. (MRUS): A Bull Case Theory [Yahoo! Finance]
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab [Yahoo! Finance]
Merus (NASDAQ:MRUS) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Merus (NASDAQ:MRUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety